Reference health
Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression
65/65 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 65 checked references that resolve
resolves10.1016/j.pneurobio.2016.10.001
Insulin resistance and Parkinson’s disease: A new target for disease modification?
resolves10.1038/nrendo.2011.138
The role of mitochondria in insulin resistance and type 2 diabetes mellitus
resolves10.1002/ana.23687
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
resolves10.1371/journal.pone.0085781
Diabetes and Risk of Parkinson's Disease: An Updated Meta-Analysis of Case-Control Studies
resolves10.1001/jamaneurol.2019.3419
Mendelian Randomization—A Journey From Obscurity to Center Stage With a Few Potholes Along the Way
resolves10.1136/bmj.b2535
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
resolves10.1007/s10654-010-9491-z
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
resolves10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M
A simple method for converting an odds ratio to effect size for use in meta-analysis
resolves10.1002/sim.3034
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
resolves10.1038/s41588-020-0637-y
Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis
resolves10.1371/journal.pmed.1002314
Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study
resolves10.1016/S1474-4422(19)30320-5
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies
resolves10.1002/mds.27845
Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts
resolves10.1093/ije/dyu005
Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome
resolves10.7554/eLife.34408
The MR-Base platform supports systematic causal inference across the human phenome
resolves10.1371/journal.pgen.1007081
Orienting the causal relationship between imprecisely measured traits using GWAS summary data
resolves10.1097/EDE.0000000000000559
Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants
resolves10.1093/ije/dyv080
Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression
resolves10.1038/s41588-018-0099-7
Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases
resolves10.1093/ije/dyy258
Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption
resolves10.1093/hmg/ddy327
Meta-analysis of genome-wide association studies
for body fat distribution in 694 649 individuals of European ancestry
resolves10.1017/S0317167100052835
A Case-Control Study of Parkinson's Disease in Urban Population of Southern Israel
resolves10.1016/j.parkreldis.2005.09.004
Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk
resolves10.1097/MD.0000000000005921
Increased risk of Parkinson disease with diabetes mellitus in a population-based study
resolves10.1136/jnnp-2020-323646
Parkinson’s disease determinants, prediction and gene–environment interactions in the UK Biobank
resolves10.2337/dc08-0688
Prospective Cohort Study of Type 2 Diabetes and the Risk of Parkinson's Disease
resolves10.1016/j.diabet.2020.08.006
Fasting plasma glucose variability in midlife and risk of Parkinson's disease: A nationwide population-based study
resolves10.1016/j.jns.2010.03.002
Case–control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan
resolves10.1016/j.parkreldis.2009.02.013
Diabetes preceding Parkinson's disease onset. A case–control study
resolves10.1093/oxfordjournals.aje.a121455
EPIDEMIOLOGIC STUDIES OF PARKINSON'S DISEASE: III. A COMMUNITY-BASED SURVEY
resolves10.1002/mds.25016
Metabolic markers or conditions preceding Parkinson's disease: A case‐control study
resolves10.1111/j.1600-0404.1994.tb01655.x
Risk-factors for Parkinson's disease: case-control study in the province of Cáceres, Spain
resolves10.1002/mds.20685
Comorbid conditions associated with Parkinson's disease: A population‐based study
resolves10.1212/01.wnl.0000271883.45010.8a
Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease
resolves10.1093/oxfordjournals.aje.a116960
Prospective Study of Cigarette Smoking and the Risk of Developing Idiopathic Parkinson's Disease
resolves10.1101/253690
Risk factors associated with Parkinson’s disease: An 11-year population-based South Korean study
resolves10.1016/j.parkreldis.2012.07.003
Parkinson disease: Associated disorders in the Norwegian population based incident ParkWest study
resolves10.1111/ane.12793
Association between Parkinson's disease and diabetes: Data from NEDICES study
resolves10.1212/WNL.0b013e3182553cc9
Clinical features of Parkinson disease when onset of diabetes came first
resolves10.1002/mds.26698
Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease
resolves10.1016/j.jns.2017.04.010
Influence of diabetes mellitus on longitudinal atrophy and cognition in Parkinson's disease
resolves10.1073/pnas.1610371113
Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson’s disease
resolves10.1111/j.1471-4159.2004.02949.x
Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology
resolves10.3389/fnins.2018.00073
The Role of Insulin/IGF-1/PI3K/Akt/GSK3β Signaling in Parkinson's Disease Dementia
resolves10.1038/nrendo.2017.151
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
resolves10.3233/JPD-191763
Ethnic Variation in the Manifestation of Parkinson’s Disease: A Narrative Review
resolves10.1016/S0140-6736(17)31585-4
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
resolves10.1093/brain/awaa262
Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes
resolves10.2147/DMSO.S100074
Novel biomarkers for prediabetes, diabetes, and associated complications
The 1 reference without a DOI — listed, not checked
no DOI — not checkedAnalysis of the relationship between type II diabetes mellitus and Parkinson's disease: a systematic review
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1002/mds.28551"><img src="https://citestamp.com/citestamped/10.1002/mds.28551/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1002/mds.28551)